Successful treatment of DOCK8 deficiency by allogeneic hematopoietic cell transplantation from alternative donors

Int J Hematol. 2023 Oct;118(4):519-525. doi: 10.1007/s12185-023-03613-y. Epub 2023 May 3.

Abstract

Dedicator of cytokinesis 8 (DOCK8) deficiency is a rare autosomal recessive inborn error of immunity (IEI) characterized by eczematous dermatitis, elevated serum IgE, and recurrent infections, comprising a seemingly hyper-IgE syndrome (HIES). DOCK8 deficiency is only curable with allogeneic hematopoietic cell transplantation (HCT), but the outcome of HCT from alternative donors is not fully understood. Here, we describe the cases of two Japanese patients with DOCK8 deficiency who were successfully treated by allogeneic HCT from alternative donors. Patient 1 underwent cord blood transplantation at the age of 16 years, and Patient 2 underwent haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide at the age of 22 years. Each patient received a fludarabine-based conditioning regimen. Their clinical manifestations, including refractory molluscum contagiosum, promptly improved post-HCT. They achieved successful engraftment and immune reconstitution without serious complications. Alternative donor sources such as cord blood and haploidentical donors can be options for allogeneic HCT for DOCK8 deficiency.

Keywords: Allogeneic HCT; Cord blood; DOCK8 deficiency; Haploidentical donor.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Cyclophosphamide
  • Cytokinesis
  • Guanine Nucleotide Exchange Factors / genetics
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Peripheral Blood Stem Cell Transplantation*
  • Young Adult

Substances

  • Cyclophosphamide
  • DOCK8 protein, human
  • Guanine Nucleotide Exchange Factors